Bessemer Group Inc Eagle Pharmaceuticals, Inc. Transaction History

Bessemer Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 09, 2022	BUY	$26.42 - $47.12 $132 - $235	5 Added 5.43%	97 $3,000
Q1 2022 May 12, 2022	BUY	$44.58 - $52.6 $4,101 - $4,839	92 New	92 $5,000
Q3 2020 Nov 12, 2020	SELL	$37.02 - $51.28 $1.14 Million - $1.58 Million	-30,800 Closed	0 $0
Q2 2020 Aug 05, 2020	BUY	$43.24 - $55.02 $56,212 - $71,526	1,300 Added 4.41%	30,800 $1.48 Million
Q1 2020 Apr 30, 2020	BUY	$34.37 - $60.07 $391,817 - $684,798	11,400 Added 62.98%	29,500 $1.36 Million
Q4 2019 Feb 04, 2020	BUY	$54.32 - $64.31 $923,440 - $1.09 Million	17,000 Added 1545.45%	18,100 $1.09 Million
Q3 2019 Nov 07, 2019	BUY	$53.25 - $59.98 $58,575 - $65,978	1,100 New	1,100 $62,000

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Bessemer Group Inc, based on Form 13F filings with the SEC.

Stay updated on Bessemer Group Inc with notifications on news.